Bioasis Technologies


C$27.2m market cap

C$0.38 last close

Bioasis Technologies is a biopharma company developing the xB3 platform to aid in the delivery of molecules to the brain using receptor mediated transcytosis. The company’s lead program is xB3-001, which is in preclinical development for brain metastases in HER2+ metastatic breast cancer patients.

Investment summary

Bioasis has developed a platform for developing drugs that can pass the blood-brain barrier (BBB) that can be used on small molecules, antibodies and enzymes. The company has licensed this platform to Prothena and Chiesi as well as advancing its internal development project xB3-001 for the treatment of beast cancer brain metastases.

Y/E Feb
Revenue (C$m)
PBT (C$m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2019A 1.4 (3.8) (2.4) (4.29) N/A N/A
2020A 0.6 (4.0) (3.4) (5.50) N/A N/A
2021E 8.7 (0.2) (0.2) (0.27) N/A N/A
2022E 3.7 (9.8) (9.8) (13.34) N/A N/A
Industry outlook

Developing a drug to pass the BBB has historically been difficult and limited to small molecules. By developing a modular platform to solve this problem Bioasis is expanding the potential diseases that can be targeted as well as providing a means to re-purpose previously developed drugs to target the brain.

Last updated on 03/03/2021
Register to receive research on Bioasis Technologies as it is published
Share price graph
Balance sheet
Forecast net cash (C$m) 1.6
Forecast gearing ratio (%) N/A
Price performance
Actual (20.8) 16.9 81.0
Relative* (22.6) 11.0 62.2
52-week high/low C$0.6/C$0.2
*% relative to local index
Key management
Deborah Rathgen Executive Chair